Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2024, Halozyme Therapeutics (HALO) reported revenue of $195.88 million, up 20.8% over the same period last year. EPS came in at $0.79, compared to $0.47 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $201.72 million, representing a surprise of -2.90%. The company delivered an EPS surprise of +14.49%, with the consensus EPS estimate being $0.69.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Revenues under collaboration agreements: $16.70 million versus the five-analyst average estimate of $16.85 million. The reported number represents a year-over-year change of +877.4%.
  • Revenues- Product sales, net: $58.58 million compared to the $61.07 million average estimate based on five analysts. The reported number represents a change of -3.6% year over year.
  • Revenues- Royalties: $120.59 million versus the five-analyst average estimate of $123.80 million. The reported number represents a year-over-year change of +21%.
  • Product sales, Net- Sales of Device Partnered Products: $12.82 million compared to the $12.95 million average estimate based on four analysts.
  • Revenues- Product sales, Net- Sales of bulk rHuPH20: $10.51 million compared to the $16.51 million average estimate based on four analysts. The reported number represents a change of -52.4% year over year.
  • Product sales, Net- Sales of proprietary products: $35.25 million compared to the $31.52 million average estimate based on four analysts.
View all Key Company Metrics for Halozyme Therapeutics here>>>

Shares of Halozyme Therapeutics have returned +2.4% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Where Will Stocks Go…

If Biden Wins? If Trump Wins?

The answers may surprise you.

Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!

Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…

1. Medical manufacturer has gained +11,000% in the last 15 years.

2. Rental company is absolutely crushing its sector.

3. Energy powerhouse plans to grow its already large dividend by 25%.

4. Aerospace and defense standout just landed a potentially $80 billion contract.

5. Giant Chipmaker is building huge plants in the U.S. 

Hurry, Download Special Report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.